ANDA 74209, held by Eugia Pharma. Cromolyn Sodium.
As of Nov 21, 2026, ANDA 74209 (Cromolyn Sodium), held by Eugia Pharma, was first approved by FDA on Apr 26, 1994, with 9 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 26, 1994 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cromolyn Sodium10MG/ML · solution;inhalation | Cromolyn Sodium | Discontinued |
| May 26, 2004 | Supplement 14Labeling | Approved | None posted |
| Apr 1, 2004 | Supplement 12Labeling | Approved | None posted |
| Dec 20, 2002 | Supplement 8Manufacturing | Approved | None posted |
| Dec 20, 2002 | Supplement 10Manufacturing | Approved | None posted |
| Jan 31, 2001 | Supplement 7Manufacturing | Approved | None posted |
| Jun 16, 1999 | Supplement 6Labeling | Approved | None posted |
| Dec 18, 1998 | Supplement 4Labeling | Approved | None posted |
| May 13, 1998 | Supplement 3Manufacturing | Approved | None posted |
| Mar 3, 1997 | Supplement 1Manufacturing | Approved | None posted |
| Apr 26, 1994 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters